Privately-held Beijing-based biotech CANbridge Life Sciences has bought the exclusive rights to seek approval for and to commercialize Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao from Puma Biotechnology (Nasdaq: PBYI).
Nerlynx was approved in the USA in July 2017 for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer.
Puma also recently agreed terms with Medison Pharma to seek regulatory approval for and commercialize the treatment in Israel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze